Steven N. Fishbane
#153,191
Most Influential Person Now
Steven N. Fishbane's AcademicInfluence.com Rankings
Steven N. Fishbanephilosophy Degrees
Philosophy
#8554
World Rank
#11961
Historical Rank
Logic
#5583
World Rank
#6992
Historical Rank

Download Badge
Philosophy
Steven N. Fishbane's Degrees
- Doctorate Medicine Albert Einstein College of Medicine
- PhD Biochemistry Albert Einstein College of Medicine
Why Is Steven N. Fishbane Influential?
(Suggest an Edit or Addition)Steven N. Fishbane's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Acute kidney injury in patients hospitalized with COVID-19 (2020) (1003)
- Acute kidney injury in patients hospitalized with COVID-19 (2020) (1003)
- KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease (2012) (793)
- Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease (2012) (757)
- Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. (2013) (564)
- A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. (2002) (306)
- Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. (2005) (287)
- The safety of intravenous iron dextran in hemodialysis patients. (1996) (248)
- Regulation of renal urate excretion: a critical review. (1998) (233)
- Self-assessed physical and mental function of haemodialysis patients. (2001) (224)
- Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. (1997) (221)
- Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management (2014) (218)
- Hemoglobin variability and mortality in ESRD. (2007) (208)
- Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. (2002) (198)
- Outcomes of patients with end-stage kidney disease hospitalized with COVID-19 (2020) (195)
- Outcomes of patients with end-stage kidney disease hospitalized with COVID-19 (2020) (195)
- Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. (2008) (194)
- Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. (2009) (192)
- N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. (2004) (185)
- A randomized trial of iron deficiency testing strategies in hemodialysis patients. (2001) (179)
- Iron management in end-stage renal disease. (1997) (173)
- Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. (2008) (173)
- Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. (1995) (172)
- The evaluation of iron status in hemodialysis patients. (1996) (170)
- Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. (2018) (164)
- Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. (2009) (158)
- Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury (2020) (156)
- Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury (2020) (156)
- Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA) (2007) (152)
- Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. (2007) (142)
- Hemoglobin variability in epoetin-treated hemodialysis patients. (2003) (141)
- Hyponatremia in Community-Acquired Pneumonia (2007) (139)
- A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. (2015) (131)
- Cerebral Salt-Wasting Syndrome: Does It Exist? (1999) (130)
- Safety in iron management. (2003) (126)
- Preservation of residual kidney function in hemodialysis patients: reviving an old concept. (2016) (124)
- Role of volume overload in dialysis-refractory hypertension. (1996) (124)
- N-acetylcysteine in the prevention of contrast-induced nephropathy. (2008) (116)
- KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease (2018) (114)
- Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management (2015) (101)
- Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. (2019) (100)
- Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. (2003) (99)
- Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. (2013) (98)
- Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. (2017) (96)
- Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients (2017) (95)
- Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. (1996) (91)
- Considerations and challenges in defining optimal iron utilization in hemodialysis. (2015) (86)
- Review of issues relating to iron and infection. (1999) (84)
- Peginesatide in patients with anemia undergoing hemodialysis. (2013) (83)
- History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. (2008) (78)
- Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib. (2015) (75)
- Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. (2002) (73)
- Iron toxicity: relevance for dialysis patients. (2014) (72)
- A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. (2019) (70)
- Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. (2021) (68)
- Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. (1997) (67)
- More on renal salt wasting without cerebral disease: response to saline infusion. (2009) (63)
- Risk for Acute Renal Failure in Patients Hospitalized for Decompensated Congestive Heart Failure (2007) (62)
- The beliefs and expectations of patients and caregivers about home haemodialysis: an interview study (2013) (61)
- Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. (2021) (60)
- Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. (2003) (60)
- Renal salt wasting without cerebral disease: diagnostic value of urate determinations in hyponatremia. (2007) (60)
- Self-Assessed Quality of Life in Peritoneal Dialysis Patients (2001) (60)
- Increased bone fractures among elderly United States hemodialysis patients. (2014) (59)
- Serum Ferritin in Chronic Kidney Disease: Reconsidering the Upper Limit for Iron Treatment (2004) (57)
- Ankle-arm blood pressure index as a marker for atherosclerotic vascular diseases in hemodialysis patients. (1995) (57)
- The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. (1995) (56)
- Update on membranoproliferative GN. (2014) (55)
- The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. (2007) (55)
- Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century (2016) (55)
- Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review (2016) (54)
- Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. (2004) (53)
- Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients (2015) (53)
- Clinical Management of Hyperkalemia. (2020) (49)
- Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. (2008) (49)
- Reducing hospital readmissions in patients with end-stage kidney disease. (2015) (48)
- Bone histology in patients with nephrotic syndrome and normal renal function. (1999) (44)
- The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? (2007) (43)
- Iron management in nondialysis-dependent CKD. (2007) (43)
- Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial. (2017) (39)
- Prostaglandin D2 synthase induces apoptosis in PC12 neuronal cells (2001) (39)
- Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. (2007) (39)
- The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. (1995) (38)
- Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients (2020) (37)
- Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease. (2019) (37)
- Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. (2012) (37)
- Cardiovascular risk evaluation before kidney transplantation. (2005) (36)
- Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19 (2021) (36)
- Hypervitaminosis A in two hemodialysis patients. (1995) (35)
- Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. (2015) (35)
- Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. (1997) (35)
- Challenges and opportunities in late-stage chronic kidney disease* (2014) (34)
- Prevalence and outcomes of hyponatremia and hypernatremia in patients hospitalized with COVID-19 (2021) (34)
- Anemia and cardiovascular risk in the patient with kidney disease. (2008) (34)
- Prevalence and outcomes of hyponatremia and hypernatremia in patients hospitalized with COVID-19 (2021) (34)
- Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection (2022) (33)
- Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses (2018) (33)
- COVID-19 in Hospitalized Patients on Chronic Peritoneal Dialysis: A Case Series (2020) (32)
- Anemia management in chronic kidney disease. (2010) (32)
- Editorials: Recombinant Human Erythropoietin: Has Treatment Reached its Full Potential? (2006) (32)
- Managing anemia in dialysis patients: hemoglobin cycling and overshoot. (2008) (31)
- Longitudinal predictors of uremic pruritus. (2013) (31)
- Increasing Hip Fractures in Patients Receiving Hemodialysis and Peritoneal Dialysis (2014) (31)
- Posttransplant anemia: the role of sirolimus. (2009) (30)
- Pharmacokinetic and Pharmacodynamic Properties of Methoxy Polyethylene Glycol‐Epoetin Beta Are Unaffected by the Site of Subcutaneous Administration 1 (2007) (30)
- Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. (2016) (29)
- A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. (2010) (29)
- Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. (2001) (29)
- Clinician beliefs and attitudes about home haemodialysis: a multinational interview study (2012) (28)
- Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study (2020) (28)
- Proximal calciphylaxis in four insulin-requiring diabetic hemodialysis patients. (1996) (28)
- Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. (2020) (27)
- Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis (2020) (27)
- Editorial: The Optimal Hemoglobin in Dialysis Patients— A Critical Review (2007) (27)
- Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer. (2014) (26)
- Beneficial effects of iron therapy in renal failure patients on hemodialysis. (1999) (26)
- Upper Limit of Serum Ferritin: Misinterpretation of the 2006 KDOQI Anemia Guidelines (2008) (25)
- Iron supplementation in renal anemia. (2006) (25)
- Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis. (2016) (24)
- Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. (2016) (22)
- Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease (2017) (22)
- The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. (2013) (21)
- Prostaglandin D2 synthase induces apoptosis in pig kidney LLC-PK1 cells (2001) (21)
- Hepatic iron in hemodialysis patients. (2004) (19)
- Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19 (2020) (19)
- Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. (2007) (19)
- Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study (2022) (19)
- Recipient Criteria Predictive of Graft Failure in Kidney Transplantation (2015) (18)
- The emerging role of biosimilar epoetins in nephrology in the United States. (2015) (18)
- Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. (2009) (17)
- Changes to the end-stage renal disease quality incentive program. (2012) (17)
- Opportunities for Increasing the Rate of Preemptive Kidney Transplantation. (2018) (17)
- Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. (2019) (17)
- Prostaglandin D(2) synthase induces apoptosis in pig kidney LLC-PK1 cells. (2001) (17)
- Iron treatment: impact of safety issues. (1998) (17)
- Quality Measurement in Wonderland: The Curious Case of a Dialysis Readmissions Measure. (2016) (16)
- Treatment Target in Polycythemia Vera (2013) (16)
- Weight trends in United States living kidney donors: Analysis of the UNOS database. (2015) (16)
- Pheochromocytoma multisystem crisis in a patient with multiple endocrine neoplasia type IIB and pyelonephritis. (2002) (16)
- The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients (2005) (15)
- Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. (2012) (15)
- Intravenous iron exposure and outcomes in patients on hemodialysis. (2014) (15)
- Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis. (2016) (15)
- Potentially Avoidable Readmissions in United States Hemodialysis Patients (2017) (15)
- Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease. (2018) (14)
- Epidemiology and Challenges to the Management of Advanced CKD. (2016) (14)
- Clofarabine-induced kidney toxicity (2014) (13)
- Removal of Foley Catheters in Live Donor Kidney Transplant Recipients on Postoperative Day 1 Does Not Increase the Incidence of Urine Leaks (2013) (13)
- Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate (2017) (12)
- ‘WhatsApp®’ening in nephrology training (2019) (12)
- The effect of hemodialysis ultrafiltration on changes in whole blood viscosity (2012) (12)
- Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure. (2018) (12)
- Paraneoplastic syndromes of the kidney. (1997) (12)
- Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia. (2002) (11)
- Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials (2020) (11)
- Diagnosis of Iron Deficiency in End‐Stage Renal Disease (1999) (10)
- Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis (2017) (10)
- Drug Insight: safety of intravenous iron supplementation with sodium ferric gluconate complex (2006) (10)
- Anemia in chronic kidney disease: status of new therapies. (2009) (10)
- Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD (2019) (10)
- Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. (1996) (10)
- The Value of Intravenous Iron: Beyond the Cave of Speculation. (2020) (9)
- The effect of improved dialytic efficiency on measures of appetite in peritoneal dialysis patients (1996) (9)
- Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation. (2021) (9)
- Is there material hazard to treatment with intravenous iron? (1999) (9)
- How we treat Renal Anemia. (2020) (9)
- Methods and rationale of the DISCOVER CKD global observational study (2021) (9)
- Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex. (2017) (8)
- The role of erythropoiesis-stimulating agents in the treatment of anemia. (2010) (8)
- Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure. (2010) (8)
- Editorial Focus: Dialysis Quality and Outcomes: Quality Outcomes and Obstacles to Their Achievement in End‐Stage Renal Disease (2002) (8)
- The effect of KT/V(urea) on nitrogen appearance and appetite in peritoneal dialysis. (1995) (8)
- Medication discrepancies in late-stage chronic kidney disease (2017) (8)
- What Is Needed to Achieve a Hemoglobin of 11.0–13.0 g/dl in End-Stage Renal Disease (2006) (7)
- Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease. (2016) (7)
- A multicenter study of the safety of intravenous iron dextran (IVFe) in hemodialysis patients (1996) (7)
- Meeting the 2012 QIP (Quality Incentive Program) clinical measures: strategies for dialysis centers. (2012) (7)
- Anemia in Non-Dialysis-Dependent CKD: To Treat or Not to Treat? (2019) (7)
- A physician's perseverance uncovers problems in a key nephrology study. (2012) (6)
- Research directions: new clinical frontiers. (2000) (6)
- Novel iron-based phosphate binders in patients with chronic kidney disease (2015) (6)
- Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection (2020) (6)
- Outcomes following Kidney transplantation in IgA nephropathy: a UNOS/OPTN analysis (2015) (6)
- Shortened Length of Stay Improves Financial Outcomes in Living Donor Kidney Transplantation (2013) (6)
- Iron deficiency in non-dialysis chronic kidney disease. (2009) (6)
- Subgroup analyses in nephrology clinical trials. (2012) (6)
- Partial characterization of apoptotic factor in Alzheimer plasma. (1999) (6)
- NARRATIVE REVIEW Iron Management in Nondialysis-Dependent CKD (2007) (6)
- Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. (2013) (6)
- The Effect of Ktn on Nitrogen Appearance and Appetite Urea in Peritoneal Dialysis (1995) (5)
- Is there an established hemoglobin target range for patients undergoing chronic dialysis? (2018) (5)
- Safety issues with iron sucrose. (2003) (5)
- Anemia treatment in chronic renal insufficiency. (2002) (5)
- Practice patterns in transitioning patients from chronic kidney disease to dialysis: a survey of United States nephrologists (2018) (5)
- Improvement of Hemodialysis Catheter Function with Tenecteplase: A Phase III, Open-Label Study: TROPICS 4 (2010) (5)
- Tenecteplase for the improvement of blood flow rate in dysfunctional hemodialysis catheters. (2010) (5)
- Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program (2022) (5)
- The New Label for Erythropoiesis Stimulating Agents: The FDA’S Sentence (2012) (5)
- Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia (2018) (5)
- How Can Erythropoeitin‐Stimulating Agent Use be Reduced in Chronic Dialysis Patients? (2013) (4)
- Phospholipase A2 Receptor Antibody-Positive Pregnancy: A Case Report. (2020) (4)
- Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease (2019) (4)
- Quality of reporting of randomization methodology in nephrology trials. (2012) (4)
- 59: Efficacy of C.E.R.A., a Continuous Erythropoietin Receptor Activator, in Treatment of Renal Anemia: Overview of 6 Global Phase 3 Trials (2007) (4)
- Nephrology Crossword: Onco-nephrology--chemotherapy agents and nephrotoxicity. (2013) (4)
- Treating desmopressin-induced hyponatremia: a case using hypertonic saline. (2013) (4)
- Review: recombinant human erythropoietin decreases the need for blood transfusions and may delay dialysis in chronic renal failure. (2002) (3)
- Abstract 16610: Efficacy and Safety of Sodium Zirconium Cyclosilicate to Treat Hyperkalemia Among Patients Taking Renin-Angiotensin-Aldosterone System Inhibitors in a 12-Month, Open-Label, Phase 3 Study: A Post Hoc Subgroup Analysis (2017) (3)
- Intravenous infusion of total dose iron in peritoneal dialysis patients: a critical appraisal. (1998) (3)
- Improving outcomes in late-stage kidney disease: the healthy transitions program. (2014) (3)
- Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease. (2019) (3)
- FP071SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY (2018) (3)
- Glomerular diseases: entering a new era. (2014) (3)
- Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting. (2021) (3)
- Cyclical cardiorenal syndrome in late-stage kidney disease . (2018) (3)
- Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review (2021) (3)
- SP421SODIUM ZIRCONIUM CYCLOSILICATE FOR HYPERKALAEMIA IN PATIENTS WITH DIABETES MELLITUS: RETROSPECTIVE ANALYSIS OF A 12 MONTH OPEN LABEL, PHASE 3 STUDY (2018) (3)
- Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies (2019) (2)
- Anemia management: a historical perspective (2021) (2)
- Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Prospective Observational Study. (2020) (2)
- What are the Considerations in Balancing Benefits and Risks in Iron Treatment? (2017) (2)
- Meeting New Challenges in the Management of Anemia of Chronic Kidney Disease Through Collaborative Care with Pharmacists (2009) (2)
- EPO adjuvant treatments: a need for more evidence. (2006) (2)
- How Can Erythropoeitin‐Stimulating Agent Use be Reduced in Chronic Dialysis Patients? (2013) (2)
- A Consensus on Current Issues and Controversies in Iron Management of Patients with Chronic Renal Failure (1999) (2)
- Forty‐eight hour kidney transplant admissions (2013) (2)
- Home Dialysis in the Time of COVID-19: Reflections on Rapidly Changing Policies (2020) (2)
- ANEMIA , CHRONIC KIDNEY DISEASE , AND CARDIOVASCULAR DISEASE : THE CLINICAL TRIALS — (2)
- The surge in nephrology consultations and inpatient dialysis services during the COVID-19 pandemic. (2020) (2)
- Hypothesis: an erythropoietin honeymoon phase exists. (2010) (2)
- Living Well With Kidney Disease and Effective Symptom Management: Consensus Conference Proceedings (2022) (2)
- More Frequent Hemoglobin ( Hb ) Measurements and Erythropoiesis-Stimulating Agent ( ESA ) Titrations are Not Associated With Increased Time in Target Hb Range (2012) (1)
- Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD (2022) (1)
- Chapter 7 – Anemia in Chronic Kidney Disease (2005) (1)
- Authors' Reply. (2021) (1)
- 58: C.E.R.A. Once Monthly Maintains Stable HB Levels in Patients with CKD on Dialysis with and without Congestive Heart Failure (CHF) (2007) (1)
- Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease (2022) (1)
- Should Target Hemoglobin Levels in Dialysis Patients be Lowered to 9–10 g/dl? (2014) (1)
- POS-328 THE BURDEN OF HYPERKALEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT (2021) (1)
- Iron management in ESRD and the role of the nephrology nurse. (1997) (1)
- Choice of erythropoiesis stimulating agent in ESRD. (2013) (1)
- The Relationship Between Medication Discrepancies and Hospitalization Risk Among Patients With Advanced CKD (2019) (1)
- Treating chronic renal insufficiency : The nephrologist vs. the internist : (A commentary) (2000) (1)
- Administrative Leadership: Nephrologists in Non-nephrology Leadership Roles. (2018) (1)
- 39: Assessing the Use of the Calcimimetic Cinacalcet with Low Dose Vitamin D Versus Escalating Doses of Vitamin D Alone in the Treatment of Secondary Hyperparathyroidism (HPT)—The Achieve Study (2007) (1)
- Abstract No. 253: A phase III, open-label study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 4 (2010) (1)
- A Woman with ESRD with Increasing Need for Erythropoietin to Maintain Hemoglobin. (2017) (1)
- Hypertension in Dialysis Patients (2000) (1)
- Anaemia: FIND-CKD: intravenous iron in predialysis CKD (2014) (1)
- Acute kidney injury in patients hospitalized withCOVID-19. (2020) (1)
- PowerPoint Slides for: Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients (2017) (1)
- Stabilizing hemoglobin levels: what's new in IV iron and anemia management? (2008) (1)
- POS-329 TREATMENT PATTERNS IN CHRONIC KIDNEY DISEASE PATIENTS WITH HYPERKALEMIA: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT (2021) (0)
- MO424: Relationship Between Itch Intensity and Patient-Reported Disease Improvement in Patients With Chronic Kidney Disease-Associated Pruritus Treated With Difelikefalin (2022) (0)
- IN-DEPTH REVIEW Iron Management in End-Stage Renal Disease (1997) (0)
- Hypoxia-inducible factor stabilizers: 27 228 patients studied, yet a role still undefined (2023) (0)
- Peginesatide for anemia in chronic kidney disease. (2013) (0)
- Identification of an apoptotic factor(AF) found in Alzheimer's disease (AD) plasma and isolated from their urine (2000) (0)
- SAT-128 Evaluating the Accuracy of Glycemic Markers and Risk of Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease by Continuous Glucose Monitoring (2019) (0)
- A New View of Iron Management in Heart Failure: What Nephrologists Need to Know. (2021) (0)
- Ferric pyrophosphate citrate for parenteral administration of maintenance iron: structure, mechanism of action, clinical efficacy and safety (2022) (0)
- Introduction to unresolved issues in the care of dialysis patients (2018) (0)
- Course of Hyperkalemia in Patients on Hemodialysis (2022) (0)
- CKD PATHOPHYSIOLOGY AND CLINICAL STUDIES (2014) (0)
- Partial characterization of apoptotic factor in Alzheimer plasma. (1999) (0)
- Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE (2022) (0)
- On Peginesatide and Anemia Treatment in CKD (2013) (0)
- Avoidable Readmissions in United States Hemodialysis Patients (2018) (0)
- FP684POTENTIALLY PREVENTABLE READMISSIONS IN CHRONIC HEMODIALYSIS PATIENTS (2015) (0)
- Roxadustat for Anemia in Patients with Chronic Kidney Disease. (2020) (0)
- Haplo-Storm induced acute kidney injury (2022) (0)
- POS-305 HOSPITALIZATIONS AND LENGTH OF STAY IN PATIENTS WITH CKD WITH AND WITHOUT HYPERKALEMIA: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT (2022) (0)
- Erratum to: Sodium Zirconium Cyclosilicate Increases Serum Bicarbonate Concentrations Among Patients with Hyperkalaemia: Exploratory Analyses from Three Randomized, Multi-Dose, Placebo-Controlled Trials (2020) (0)
- Iron Deficiency in Dialysis Patients: Current Views on Diagnosis and Management (1999) (0)
- Induction of apoptosis in neuronal cells by a plasma factor found in Alzheimer's disease (AD) (2000) (0)
- Chapter 50 – Anemia in Patients With End-Stage Kidney Disease (2017) (0)
- POS-258 CARDIOVASCULAR OUTCOMES AND EXPLORATORY ANALYSES BY ACHIEVED HB LEVELS IN THE POOLED PHASE 3 ROXADUSTAT STUDIES OF NON-DIALYSIS-DEPENDENT PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE (2021) (0)
- Treatment with Erythropoiesis Stimulating Agents in Patients with Chronic Kidney Disease Complicated by Cancer (2017) (0)
- Serum potassium laboratory reference ranges influence provider treatment behaviors for hyperkalemia. (2020) (0)
- P0242SUBGROUP EFFICACY ANALYSIS OF SODIUM ZIRCONIUM CYCLOSILICATE (SZC) IN HYPERKALAEMIC HAEMODIALYSIS PATIENTS IN THE DIALIZE STUDY (2020) (0)
- P0189SODIUM ZIRCONIUM CYCLOSILICATE CORRECTS HYPERKALAEMIA WITHIN 72 HOURS AMONG OUTPATIENTS WITH SEVERE HYPERKALAEMIA (BASELINE SERUM POTASSIUM ≥6 MMOL/L) REGARDLESS OF RENAL FUNCTION LEVEL OR RAASI USE: POST HOC SUBGROUP ANALYSIS OF A PHASE 3 TRIAL (2020) (0)
- Dialysis: ESA responsiveness and outcomes in patients on hemodialysis (2012) (0)
- POS-284 CARDIOVASCULAR OUTCOMES AND EXPLORATORY ANALYSES BY ACHIEVED HB LEVELS IN POOLED PHASE 3 TRIALS OF ROXADUSTAT IN DIALYSIS-DEPENDENT PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE (2021) (0)
- FC 077LONG-TERM SAFETY OF TENAPANOR FOR THE CONTROL OF SERUM PHOSPHORUS IN PATIENTS WITH CKD ON DIALYSIS (2021) (0)
- Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients (2022) (0)
- Resource Use in Adult Dual Kidney Transplantation(DKT): Analysis of the United Network of Organ Sharing(UNOS) Database.: Abstract# C1861 (2014) (0)
- Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis. (2023) (0)
- P0198SODIUM ZIRCONIUM CYCLOSILICATE INCREASES SERUM BICARBONATE CONCENTRATIONS AMONG PATIENTS WITH HYPERKALAEMIA: RESULTS FROM THREE RANDOMIZED, MULTI-DOSE, PLACEBO CONTROLLED TRIALS (2020) (0)
- Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623 (2022) (0)
- Introduction: Iron Management in Chronic Kidney Disease. (2016) (0)
- Difelikefalin in Hemodialysis Patients with Pruritus. Reply. (2020) (0)
- P0220EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE (SZC) IN HAEMODIALYSIS PATIENTS WITH SEVERE HYPERKALAEMIA IN THE DIALIZE STUDY (2020) (0)
- 170 - Safety and Efficacy of Ferric Citrate in Patients with Nondialysis-Dependent Chronic Kidney Disease and Iron Deficiency Anemia: Post Hoc Analysis in Patients with or Without Heart Failure (2017) (0)
- AN ANALYSIS OF AN EMERGENCY DEPARTMENT TRIAGE PROGRAM FOR RAPID IDENTIFICATION OF COMMUNITY-ACQUIRED PNEUMONIA (2008) (0)
- MO538 THE SHORT-TERM IMPACT OF HIGH DOSE INTRAVENOUS IRON USE ON RENAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND IRON DEFICIENCY WITHOUT ANAEMIA - A POST-HOC ANALYSIS OF A MULTICENTRE RANDOMIZED CONTROLLED TRIAL* (2021) (0)
- 193: Safety and Tolerability of C.E.R.A. (A Continuous Erythropoietin Receptor Activator) in Patients With Chronic Kidney Disease: Pooled Data From Ten Phase II-III Trials (2007) (0)
- Pruritus in chronic kidney disease (2022) (0)
- The authors reply. (2020) (0)
- POS-503 EVALUATING CHRONIC KIDNEY DISEASE PROGRESSION: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT (2021) (0)
- Improving Detection and Management of Anemia in CKD. (2022) (0)
- Announcement / Book Reviews (1999) (0)
- MO539HEMATOLOGIC EFFICACY OF VADADUSTAT FOR ANEMIA IN PATIENTS WITH KIDNEY FAILURE ON DIALYSIS (2021) (0)
- Intravenous iron treatment: a comparison of available drugs (2002) (0)
- 306 Risk of Acute Kidney Injury in COVID-19 is Increased in African Americans With APOL1 High-Risk Genotype (2021) (0)
- POS-283 HEMOGLOBIN (HB) CORRECTION WITH ROXADUSTAT IS ASSOCIATED WITH IMPROVED IRON HOMEOSTASIS IN PATIENTS WITH NON-DIALYSIS-DEPENDENT (NDD) AND DIALYSIS-DEPENDENT (DD) CHRONIC KIDNEY DISEASE (CKD) (2021) (0)
- Efficacy of Treatments Targeting the Calcium- Sensing Receptor, Ca R, and Vitamin D Receptor, V D R, in Controlling Parathyroid Hormone, P T H, in Hemodialysis Patients (2008) (0)
- Use of TIMP-2 and IGFBP-7 for prediction of postoperative acute kidney injury after cardiac surgery. (2022) (0)
- WCN23-0671 BASELINE CHARACTERISTICS OF PATIENTS ENROLLED IN THE DISCOVER CKD PROSPECTIVE STUDY (2023) (0)
- Pruritus in chronic kidney disease. (2022) (0)
- Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe Hyperkalemia (2021) (0)
- Unmet Medical Needs in Chronic-Kidney-Disease-Associated Pruritus (2021) (0)
- Refractory anemia in a patient with allergy to intravenous iron drugs. (2006) (0)
- Anemia in CKD in Primary Care: Executive Summary. (2022) (0)
- Dual Adult Kidney Transplants (DKT):Analysis of the United Network of Organ Sharing (UNOS) Database 2006-2011.: Abstract# 2873 (2014) (0)
- MO214EVALUATION OF THE EFFECT OF A POTASSIUM BINDER ON ARRHYTHMIA-RELATED CARDIOVASCULAR OUTCOMES IN PATIENTS ON CHRONIC HAEMODIALYSIS WITH RECURRENT HYPERKALAEMIA: DESIGN AND RATIONALE FOR THE SODIUM ZIRCONIUM CYCLOSILICATE DIALIZE-OUTCOMES STUDY (2021) (0)
- Enalapril delayed end-stage renal failure in patients with chronic renal failure and hypertension (1995) (0)
- POS-282 ROXADUSTAT TREATMENT RESULTS IN CONSISTENT IMPROVEMENTS IN HEMOGLOBIN (HB) VERSUS PLACEBO: AN ANALYSIS OF THREE MULTINATIONAL RCTS IN PATIENTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Steven N. Fishbane?
Steven N. Fishbane is affiliated with the following schools: